{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:32:50Z","timestamp":1793845970998,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01208-x","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T10:01:36Z","timestamp":1718964096000},"page":"1959-1968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib"],"prefix":"10.1007","volume":"14","author":[{"given":"Brittany","family":"Craiglow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dutronc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"1208_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LH, Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"key":"1208_CR2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/jdv.18926","volume":"37","author":"A Muntyanu","year":"2023","unstructured":"Muntyanu A, Sofianne G, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023;37:1490\u2013520.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1208_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000530356","volume":"9","author":"L Drake","year":"2023","unstructured":"Drake L, Li SJ, Reyes-Hadsall S, et al. Post-Traumatic stress disorder in patients with alopecia areata: a survey study in the USA. Skin Appendage Disord. 2023;9(5):342\u20135.","journal-title":"Skin Appendage Disord"},{"issue":"4","key":"1208_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000529924","volume":"9","author":"SJ Li","year":"2023","unstructured":"Li SJ, Reyes-Hadsall S, Drake L, et al. Experiencing workplace bullying in patients with alopecia areata: a cross-sectional survey study. Skin Appendage Disord. 2023;9(4):258\u201361.","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"1208_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","volume":"13","author":"K Gandhi","year":"2023","unstructured":"Gandhi K, Shy ME, Ray M, et al. The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata. Dermatol Ther (Heidelb). 2023;13(1):285\u201398.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1208_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s13555-022-00710-4","volume":"12","author":"A Mostaghimi","year":"2022","unstructured":"Mostaghimi A, Xenakis J, Meche A, et al. Economic burden and healthcare resource use of alopecia areata in an insured population in the USA. Dermatol Ther (Heidelb). 2022;12(4):1027\u201340.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1208_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11(3):867\u201383.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"18","key":"1208_CR8","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"1","key":"1208_CR9","doi-asserted-by":"publisher","first-page":"2227299","DOI":"10.1080\/09546634.2023.2227299","volume":"34","author":"BM Piraccini","year":"2023","unstructured":"Piraccini BM, Ohyama M, Craiglow B, et al. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat. 2023;34(1):2227299.","journal-title":"J Dermatolog Treat"},{"key":"1208_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jvc2.269","volume":"3","author":"B Piraccini","year":"2024","unstructured":"Piraccini B, Ohyama M, Craiglow B, et al. Improvement in health-related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: results from two international randomized controlled trials. JEADV Clin Pract. 2024;3:242\u20138. https:\/\/doi.org\/10.1002\/jvc2.269.","journal-title":"JEADV Clin Pract"},{"issue":"3","key":"1208_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1208_CR12","unstructured":"Chren MM. SKINDEX-16 for alopecia areata (SKINDEX-16 for AA). 2018. https:\/\/eprovide.mapi-trust.org\/instruments\/skindex-16-for-alopecia-areata#contact_and_conditions_of_use. Accessed 29 Nov 2022."},{"issue":"2","key":"1208_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","volume":"30","author":"M-M Chren","year":"2012","unstructured":"Chren M-M. The skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231\u20136.","journal-title":"Dermatol Clin"},{"issue":"2","key":"1208_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","volume":"5","author":"M-M Chren","year":"2001","unstructured":"Chren M-M, Lasek RJ, Sahay AP, Sands LP, et al. Measurement properties of skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105\u201310.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"1208_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"1208_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, et al. The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1208_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2017.10.046","volume":"78","author":"LY Liu","year":"2018","unstructured":"Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. J Am Acad Dermatol. 2018;78(3):597-9.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1208_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","volume":"189","author":"B King","year":"2023","unstructured":"King B, Shapiro J, Ohyama M, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666\u201373. https:\/\/doi.org\/10.1093\/bjd\/ljad253.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1208_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow B, Dai F, King BA, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"1208_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.","journal-title":"JCI Insight"},{"issue":"1","key":"1208_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"1208_CR22","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, et al. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62-8.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"1","key":"1208_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.21055","volume":"187","author":"AE Macbeth","year":"2022","unstructured":"Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022;187(1):73\u201381.","journal-title":"Br J Dermatol"},{"key":"1208_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38:583\u201393. https:\/\/doi.org\/10.1111\/jdv.19665.","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1007\/s13555-024-01265-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01208-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T06:15:35Z","timestamp":1729059335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01208-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01208-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-024-01265-2","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-024-01265-2","URL":"https:\/\/doi.org\/10.1007\/s13555-024-01265-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brittany Craiglow has received support for medical writing from Eli Lilly; consulting fees from Dermavant, Eli Lilly, Incyte, Pfizer, Concert Pharmaceuticals, Regeneron, Sanofi-Genzyme; payment and\/or honoraria from Abbvie, Eli Lilly and Company, Incyte Corporation, Pfizer, Regeneron, and Sanofi Genzyme; support for attending meetings\/travel from Eli Lilly and Pfizer; and is a member of the Board of Directors and Medical and Scientific Advisory Board and of the Foundation for Ichthyosis and Related Skin Types. Yang Won Lee has received support for the clinical trial from Eli Lilly and Company. Sergio Va\u00f1\u00f3\u2011Galv\u00e1n reports consulting fees and payment\/honoraria from Eli Lilly and Company and Pfizer. Alexander Egeberg has received research funding from Abbvie, Danish National Psoriasis Foundation, Eli Lilly, Janssen, Kgl. Hofbundtmager Aage Bangs Foundation, Novartis, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Almirall, Simon Spies Foundation; consulting fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Galapagos NV, Galderma, Janssen, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis, Boehringer Ingelheim, UCB, UNION Therapeutics, Horizon Therapeutics; payment\/honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Janssen, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis, UCB; and support for attending congresses from Abbvie, Eli Lilly, Bristol-Myers Squibb, Janssen. He has participated on a data safety monitoring board\/advisory boards from Samsung Bioepis and Horizon Therapeutics; and has stock options from LEO Pharma; Alexander Egeberg is an employee of LEO Pharma. Yves Dutronc, Frederick Durand, Evangeline Pierce, Guanglei Yu, and Yun\u2011Fei Chen are employees and shareholders of Eli Lilly and Company. Arash Mostaghimi has been a consultant for Hims and Hers, Abbvie, Sun Pharmaceuticals, Pfizer, Digital Diagnostics, Aslan, Boehringer Ingelheim, ACOM and Olaplex; received support for materials from Lilly; received royalties for the BELA, BETA, and ALFA scales outside of this work;\u00a0received payment or honoraria from Lilly; received support for travel from Lilly; and is Secretary\/Treasurer for the Medical Dermatology Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trials were conducted in accordance with the ethical principles of the Declaration of Helsinki of 1964 and its subsequent amendments and with Good Clinical Practice guidelines, and the research protocols were approved by each center\u2019s institutional review board or ethics committee. All patients provided written informed consent for participation in the trials<i>.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}